Literature DB >> 9407503

Influence of endotoxin contamination on anti-GBM antibody induced glomerular injury in rats.

A M Karkar1, A J Rees.   

Abstract

It is accepted that the main determinant of glomerular injury in experimental nephrotoxic nephritis is the administered dose of anti-glomerular basement membrane (GBM) antibody. However, there are other factors that can enhance the severity of such injury including small doses of bacterial lipopolysaccharide (LPS). In the present study, we have assessed whether preparations of anti-GBM antibody contaminated with different concentrations of endotoxin could influence the severity of glomerular injury in the heterologous phase of nephrotoxic nephritis. We have also examined the efficacy of different laboratory methods to isolate an endotoxin-free anti-GBM antibody, and to purify anti-GBM antibody preparations from endotoxin. Preparations of anti-GBM antibody (nephrotoxic globulin) isolated from nephrotoxic serum by the sodium sulphate precipitation method contained variable concentrations of endotoxin. Administration of these preparations in equal doses into clean rats, which had no established acute phase response, markedly aggravated the severity of glomerular injury. However, preparations contained less than 50 pg/ml of endotoxin appeared to have no significant effect on such injury. Furthermore, isolation of anti-GBM antibody from nephrotoxic serum by affinity chromatography, using Staphylococcus protein-A column, proved to be a reliable method not only for the isolation of an IgG (nephrotoxic antibody) free from other serum contaminants, but also for purification of endotoxin contaminated preparations of anti-GBM antibody. These observations have practical implications in studying models of nephritis as our results show that the glomerular injury, which is usually considered to be a sole function of the mass of antibody bound to GBM, is profoundly influenced by minor endotoxin contamination of the anti-GBM antibody.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407503     DOI: 10.1038/ki.1997.488

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

Review 1.  Role of T cells and dendritic cells in glomerular immunopathology.

Authors:  Christian Kurts; Felix Heymann; Veronika Lukacs-Kornek; Peter Boor; Jürgen Floege
Journal:  Semin Immunopathol       Date:  2007-10-23       Impact factor: 9.623

Review 2.  Kidney dendritic cells: fundamental biology and functional roles in health and disease.

Authors:  Christian Kurts; Florent Ginhoux; Ulf Panzer
Journal:  Nat Rev Nephrol       Date:  2020-05-05       Impact factor: 28.314

3.  Tocilizumab monotherapy uncovered the role of the CCL22/17-CCR4+ Treg axis during remission of crescentic glomerulonephritis.

Authors:  Ryota Sakai; Minako Ito; Keiko Yoshimoto; Shunsuke Chikuma; Takahiko Kurasawa; Tsuneo Kondo; Katsuya Suzuki; Tsutomu Takeuchi; Koichi Amano; Akihiko Yoshimura
Journal:  Clin Transl Immunology       Date:  2020-10-30

4.  Inhibition of semaphorin-3a suppresses lipopolysaccharide-induced acute kidney injury.

Authors:  Xiaofang Tian; Hua Gan; Yizhou Zeng; Hongfei Zhao; Rong Tang; Yunfeng Xia
Journal:  J Mol Med (Berl)       Date:  2018-06-16       Impact factor: 4.599

5.  Antibody-mediated glomerulonephritis in mice: the role of endotoxin, complement and genetic background.

Authors:  M G Robson; H T Cook; C D Pusey; M J Walport; K A Davies
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

Review 6.  Protein purification strategies must consider downstream applications and individual biological characteristics.

Authors:  Kim Remans; Mario Lebendiker; Celeste Abreu; Mariano Maffei; Shaila Sellathurai; Marina M May; Ondřej Vaněk; Ario de Marco
Journal:  Microb Cell Fact       Date:  2022-04-07       Impact factor: 5.328

7.  ASK1 inhibitor treatment suppresses p38/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritis.

Authors:  Liv A Amos; Frank Y Ma; Greg H Tesch; John T Liles; David G Breckenridge; David J Nikolic-Paterson; Yingjie Han
Journal:  J Cell Mol Med       Date:  2018-07-11       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.